Chardan Capital Markets analyst Gbola Amusa downgraded Moderna (NASDAQ: MRNA) from Buy to Neutral with a price target of $191.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE